Skip to content
PubMed This is a summary of 105 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 105 referenced papers

Top Authors

Peter A. Merkel
University of Pennsylvania
Benjamin Terrier
Hôpital Cochin
Florence E. Roufosse
Université Libre de Bruxelles
Michael E. Wechsler
National Jewish Health
Vincent Cottin
Lyon 1 Université
Maria Cinta Cid
Hospital Clínic de Barcelona
David R.W. Jayne
University of Cambridge
Ulrich Specks
Mayo Clinic
Matthieu Groh
Hôpital Foch
Augusto Vaglio
Meyer Children's Hospital

Top Institutions

Ranked by publications Top 10 institutions

References

References (105)
  1. 1

    Eosinophilic myocarditis: case series and literature review.

    Sohn KH, Song WJ, Kim BK, et al.

    Asia Pacific allergy 2015; (5(2)):123-7 doi:10.5415/apallergy.2015.5.2.123.

    PMID: 25938077
  2. 2

    Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

    Groh M, Pagnoux C, Baldini C, et al.

    European journal of internal medicine 2015; (26(7)):545-53.

    PMID: 25971154
  3. 3

    KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

    Schwaab J, Umbach R, Metzgeroth G, et al.

    American journal of hematology 2015; (90(9)):774-7 doi:10.1002/ajh.24075.

    PMID: 26017288
  4. 4

    [Cardiac involvement in Churg-Strauss syndrome].

    Brucato A, Maestroni S, Masciocco G, et al.

    Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.

    PMID: 26418389
  5. 5

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  6. 6

    Pulmonary embolism, deep vein thrombosis and recurrent bone cysts in a patient with hypereosinophilic syndrome.

    Chen TS, Xing LH, Wang SL, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(7)):831-834 doi:10.1097/MBC.0000000000000501.

    PMID: 26780165
  7. 7

    Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.

    Khoury P, Desmond R, Pabon A, et al.

    Allergy 2016; (71(6)):803-10 doi:10.1111/all.12843.

    PMID: 26797802
  8. 8

    [Hypereosinophilic syndrome with first presentation of pulmonary embolism and extensive venous thrombosis: a case report and literature review].

    Xu W, Guo W, Yang T

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2015; (38(12)):912-7.

    PMID: 26850893
  9. 9

    Severe Prolonged Cough as Presenting Manifestation of FIP1L1-PDGFRA+ Chronic Eosinophilic Leukaemia: A Widely Ignored Association.

    Roufosse F, Heimann P, Lambert F, et al.

    Respiration; international review of thoracic diseases 2016; (91(5)):374-9 doi:10.1159/000446076.

    PMID: 27164940
  10. 10

    Blood and Bone Marrow Evaluation for Eosinophilia.

    Boyer DF

    Archives of pathology & laboratory medicine 2016; (140(10)):1060-7 doi:10.5858/arpa.2016-0223-RA.

    PMID: 27684977
  11. 11

    Hypereosinophilic syndrome.

    Noh HR, Magpantay GG

    Allergy and asthma proceedings 2017; (38(1)):78-81 doi:10.2500/aap.2017.38.3995.

    PMID: 28052805
  12. 12

    Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

    Wang SA, Hasserjian RP, Tam W, et al.

    Haematologica 2017; (102(8)):1352-1360 doi:10.3324/haematol.2017.165340.

    PMID: 28495918
  13. 13

    Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.

    Kraakman MJ, Lee MK, Al-Sharea A, et al.

    The Journal of clinical investigation 2017; (127(6)):2133-2147.

    PMID: 28504650
  14. 14

    Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

    Wechsler ME, Akuthota P, Jayne D, et al.

    The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.

    PMID: 28514601
  15. 15

    Eosinophilic myocarditis and hypereosinophilic syndrome.

    Boussir H, Ghalem A, Ismaili N, El Ouafi N

    Journal of the Saudi Heart Association 2017; (29(3)):211-213 doi:10.1016/j.jsha.2016.11.001.

    PMID: 28652675
  16. 16

    Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

    Thiel J, Troilo A, Salzer U, et al.

    The journal of allergy and clinical immunology. In practice 2017; (5(6)):1556-1563 doi:10.1016/j.jaip.2017.07.027.

    PMID: 28916432
  17. 17

    Eosinophilic Myocarditis.

    Cheung CC, Constantine M, Ahmadi A, et al.

    The American journal of the medical sciences 2017; (354(5)):486-492 doi:10.1016/j.amjms.2017.04.002.

    PMID: 29173361
  18. 18

    Imatinib for the treatment of hypereosinophilic syndromes.

    Helbig G

    Expert review of clinical immunology 2018; (14(2)):163-170 doi:10.1080/1744666X.2018.1425142.

    PMID: 29303368
  19. 19

    Eosinophil-Related Disease and the Skin.

    Leiferman KM, Peters MS

    The journal of allergy and clinical immunology. In practice 2018; (6(5)):1462-1482.e6 doi:10.1016/j.jaip.2018.06.002.

    PMID: 29902530
  20. 20

    An Approach to the Evaluation of Persistent Hypereosinophilia in Pediatric Patients.

    Schwartz JT, Fulkerson PC

    Frontiers in immunology 2018; (9()):1944 doi:10.3389/fimmu.2018.01944.

    PMID: 30233571
  21. 21

    Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome.

    Li D, Xu L, Lin D, et al.

    Respiratory medicine case reports 2018; (25()):213-215 doi:10.1016/j.rmcr.2018.09.006.

    PMID: 30237972
  22. 22

    Thrombosis in the portal venous system caused by hypereosinophilic syndrome: A case report.

    Lin J, Huang X, Zhou W, et al.

    Medicine 2018; (97(48)):e13425 doi:10.1097/MD.0000000000013425.

    PMID: 30508952
  23. 23

    Reactive thrombocytosis in acute infectious diseases: Prevalence, characteristics and timing.

    Schattner A, Kadi J, Dubin I

    European journal of internal medicine 2019; (63()):42-45 doi:10.1016/j.ejim.2019.02.010.

    PMID: 30795883
  24. 24

    Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report.

    Khalid F, Holguin F

    The American journal of case reports 2019; (20()):381-384 doi:10.12659/AJCR.912747.

    PMID: 30902963
  25. 25

    Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

    Puéchal X, Pagnoux C, Baron G, et al.

    Rheumatology (Oxford, England) 2019; (58(12)):2107-2116 doi:10.1093/rheumatology/kez139.

    PMID: 31056661
  26. 26

    A case of eosinophilic granulomatosis with polyangiitis complicated with a similar condition to IgG4 related lung disease.

    Zhou L, Cao F, Fan S, et al.

    BMC pulmonary medicine 2019; (19(1)):154 doi:10.1186/s12890-019-0917-4.

    PMID: 31426769
  27. 27

    Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia.

    Costagliola G, Marco SD, Comberiati P, et al.

    Current pediatric reviews 2020; (16(2)):81-88 doi:10.2174/1573396315666191114150438.

    PMID: 31729944
  28. 28

    Causes of hypereosinophilia in 100 consecutive patients.

    Moller D, Tan J, Gauiran DTV, et al.

    European journal of haematology 2020; (105(3)):292-301 doi:10.1111/ejh.13437.

    PMID: 32364630
  29. 29

    Hypereosinophilia with Concurrent Venous Thromboembolism: Clinical Features, Potential Risk Factors, and Short-term Outcomes in a Chinese Cohort.

    Liu Y, Meng X, Feng J, et al.

    Scientific reports 2020; (10(1)):8359 doi:10.1038/s41598-020-65128-4.

    PMID: 32433573
  30. 30

    International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis.

    Moiseev S, Bossuyt X, Arimura Y, et al.

    American journal of respiratory and critical care medicine 2020; (202(10)):1360-1372 doi:10.1164/rccm.202005-1628SO.

    PMID: 32584187
  31. 31

    Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.

    Tolebeyan A, Mohammadi O, Vaezi Z, Amini A

    Cureus 2020; (12(8)):e9684 doi:10.7759/cureus.9684.

    PMID: 32923277
  32. 32

    Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.

    Roufosse F, Kahn JE, Rothenberg ME, et al.

    The Journal of allergy and clinical immunology 2020; (146(6)):1397-1405 doi:10.1016/j.jaci.2020.08.037.

    PMID: 32956756
  33. 33

    Loeffler's Endocarditis: An Integrated Multimodality Approach.

    Polito MV, Hagendorff A, Citro R, et al.

    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2020; (33(12)):1427-1441 doi:10.1016/j.echo.2020.09.002.

    PMID: 33129649
  34. 34

    Experimental Modeling of Eosinophil-Associated Diseases.

    Upparahalli Venkateshaiah S, Manohar M, Kandikattu HK, Mishra A

    Methods in molecular biology (Clifton, N.J.) 2021; (2241()):275-291 doi:10.1007/978-1-0716-1095-4_21.

    PMID: 33486743
  35. 35

    A case of hypereosinophilic syndrome with STAT5b N642H mutation.

    Ding F, Wu C, Li Y, et al.

    Oxford medical case reports 2021; (2021(1)):omaa129 doi:10.1093/omcr/omaa129.

    PMID: 33542831
  36. 36

    Venous thrombosis and predictors of relapse in eosinophil-related diseases.

    Réau V, Vallée A, Terrier B, et al.

    Scientific reports 2021; (11(1)):6388 doi:10.1038/s41598-021-85852-9.

    PMID: 33737704
  37. 37

    Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.

    Fukuchi M, Kamide Y, Ueki S, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(9)):1683-1693 doi:10.1002/art.41727.

    PMID: 33750029
  38. 38

    Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America.

    Doubelt I, Cuthbertson D, Carette S, et al.

    ACR open rheumatology 2021; (3(6)):404-412 doi:10.1002/acr2.11263.

    PMID: 34032390
  39. 39

    Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

    Valent P, Degenfeld-Schonburg L, Sadovnik I, et al.

    Seminars in immunopathology 2021; (43(3)):423-438 doi:10.1007/s00281-021-00863-y.

    PMID: 34052871
  40. 40

    Hypereosinophilic syndrome: considerations for the cardiologist.

    Bondue A, Carpentier C, Roufosse F

    Heart (British Cardiac Society) 2022; (108(3)):164-171 doi:10.1136/heartjnl-2020-317202.

    PMID: 34172539
  41. 41

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(8)):1366-1383 doi:10.1002/art.41773.

    PMID: 34235894
  42. 42

    Normalization of left ventricular filling pressure after cardiac surgery for the Loeffler's endocarditis: a case report.

    Carcaterra A, Mock S, Müller H, Testuz A

    European heart journal. Case reports 2021; (5(6)):ytab189 doi:10.1093/ehjcr/ytab189.

    PMID: 34263118
  43. 43

    Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations.

    Leiva O, Baker O, Jenkins A, et al.

    JAMA network open 2021; (4(8)):e2119812 doi:10.1001/jamanetworkopen.2021.19812.

    PMID: 34357393
  44. 44

    World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.

    PMID: 34533850
  45. 45

    Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital.

    Eldaabossi SAM, Awad A, Anshasi N

    Respiratory medicine case reports 2021; (34()):101520 doi:10.1016/j.rmcr.2021.101520.

    PMID: 34692397
  46. 46

    Literature reviews of stroke with hypereosinophilic syndrome.

    Ono R, Iwahana T, Kato H, et al.

    International journal of cardiology. Heart & vasculature 2021; (37()):100915 doi:10.1016/j.ijcha.2021.100915.

    PMID: 34888412
  47. 47

    2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.

    Grayson PC, Ponte C, Suppiah R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(3)):386-392 doi:10.1002/art.41982.

    PMID: 35106968
  48. 48

    Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease.

    Kubo S, Kanda R, Nawata A, et al.

    RMD open 2022; (8(1)) doi:10.1136/rmdopen-2021-002086.

    PMID: 35260476
  49. 49

    [Ten questions about eosinophilic myocarditis].

    Pagura L, Imazio M, Merlo M, Sinagra G

    Giornale italiano di cardiologia (2006) 2022; (23(4)):259-267 doi:10.1714/3766.37535.

    PMID: 35343477
  50. 50

    Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.

    Reiter A, Lefevre G, Cid MC, et al.

    Frontiers in immunology 2022; (13()):840974 doi:10.3389/fimmu.2022.840974.

    PMID: 35493455
  51. 51

    Rare Case of a Young Male Presented with Abdominal Pain, Solid Colon Tumors, and Eosinophilia, Followed by Tremendous Thromboembolic Complications and Eventually Diagnosed with Idiopathic Hypereosinophilic Syndrome.

    Zemleduch T, Czapla A, Kimla P, Kudliński B

    Case reports in medicine 2022; (2022()):1424749 doi:10.1155/2022/1424749.

    PMID: 35646123
  52. 52

    Portal Vein Thrombosis as a Cause of Undetermined Thrombocytopenia with Liver Dysfunction in a Patient with Eosinophilic Granulomatosis with Polyangiitis.

    Oka N, Yoshida Y, Sugimoto T, et al.

    Internal medicine (Tokyo, Japan) 2023; (62(1)):123-127 doi:10.2169/internalmedicine.9485-22.

    PMID: 35705273
  53. 53

    2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

    Farge D, Frere C, Connors JM, et al.

    The Lancet. Oncology 2022; (23(7)):e334-e347 doi:10.1016/S1470-2045(22)00160-7.

    PMID: 35772465
  54. 54

    Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?

    Iurlo A, Cattaneo D

    Blood reviews 2023; (58()):101014 doi:10.1016/j.blre.2022.101014.

    PMID: 36153195
  55. 55

    [ACUTE VISION LOSS ASSOCIATED WITH HYPEREOSINOPHILIC SYNDROME].

    Man Peles I, Goldenberg-Cohen N

    Harefuah 2022; (161(10)):603-605.

    PMID: 36315204
  56. 56

    Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.

    Akiely R, Almasri F, Almasri N, Abu-Ghosh A

    Frontiers in pediatrics 2022; (10()):1059527 doi:10.3389/fped.2022.1059527.

    PMID: 36589160
  57. 57

    Diagnostic spectrum of hypereosinophilia based on bone marrow pathology: 10 years' experience at a tertiary care hospital.

    Kim H, Cho YU

    International journal of laboratory hematology 2023; (45(3)):328-336 doi:10.1111/ijlh.14025.

    PMID: 36756990
  58. 58

    Acute Myeloid Leukaemia With Translocation (8;21) Masquerading as Peripheral Blood Eosinophilia Having Dysplastic Features: A Diagnostic Challenge.

    Singh A, Tripathi T, Singh A, et al.

    Cureus 2023; (15(1)):e33858 doi:10.7759/cureus.33858.

    PMID: 36819451
  59. 59

    EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.

    Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.

    Annals of the rheumatic diseases 2024; (83(1)):30-47 doi:10.1136/ard-2022-223764.

    PMID: 36927642
  60. 60

    [Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].

    Holle JU, Moosig F

    Zeitschrift fur Rheumatologie 2023; (82(4)):307-320 doi:10.1007/s00393-023-01345-2.

    PMID: 37099180
  61. 61

    French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.

    Groh M, Rohmer J, Etienne N, et al.

    Orphanet journal of rare diseases 2023; (18(1)):100 doi:10.1186/s13023-023-02696-4.

    PMID: 37122022
  62. 62

    Pediatric hypereosinophilic syndrome associated with liver damage, portal vein, splenic vein and superior mesenteric vein thromboses: a case report.

    Zheng HT, Xu Y, Yan XY, et al.

    BMC pediatrics 2023; (23(1)):233 doi:10.1186/s12887-023-04014-0.

    PMID: 37173706
  63. 63

    Eosinophilic granulomatosis with polyangiitis - Advances in pathogenesis, diagnosis, and treatment.

    Fijolek J, Radzikowska E

    Frontiers in medicine 2023; (10()):1145257 doi:10.3389/fmed.2023.1145257.

    PMID: 37215720
  64. 64

    [Risk Factors and Prognosis of Cardiovascular Damage in Hypereosinophilia].

    Zhang WJ, Zhang QK, Wei XF, et al.

    Zhongguo shi yan xue ye xue za zhi 2023; (31(3)):810-815 doi:10.19746/j.cnki.issn.1009-2137.2023.03.028.

    PMID: 37356944
  65. 65

    HES and EGPA: Two Sides of the Same Coin.

    Khoury P, Akuthota P, Kwon N, et al.

    Mayo Clinic proceedings 2023; (98(7)):1054-1070 doi:10.1016/j.mayocp.2023.02.013.

    PMID: 37419574
  66. 66

    The portrait of a stranger: the hypereosinophilic syndrome with cardiac involvement.

    Ivănescu AC, Petre A, Marincaș AS, et al.

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2023; (61(4)):222-227 doi:10.2478/rjim-2023-0016.

    PMID: 37493620
  67. 67

    Complement Factor I Gene Variant in an Atypical Hemolytic Uremic Syndrome Triggered by Hypereosinophilia Syndrome.

    Banjongjit A, Kittanamongkolchai W, Kanjanabuch T

    Nephron 2023; (147(11)):701-706 doi:10.1159/000531879.

    PMID: 37611541
  68. 68

    Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine.

    Mencarelli L, Moi L, Dewarrat N, et al.

    Vaccines 2023; (11(8)) doi:10.3390/vaccines11081335.

    PMID: 37631903
  69. 69

    Coexistence of IgG4-related disease and ANCA-associated vasculitis: case report and review of the literature.

    Korkmaz C, Yıldırım R, Dinler M, Cansu DU

    Rheumatology international 2024; (44(3)):557-572 doi:10.1007/s00296-023-05419-x.

    PMID: 37634133
  70. 70

    FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus.

    Locke M, Suen RM, Williamson AK, Nieto MJ

    Cureus 2023; (15(8)):e43138 doi:10.7759/cureus.43138.

    PMID: 37692703
  71. 71

    Case report: Serious unexpected vascular events in two patients with lymphocytic variant hypereosinophilic syndrome.

    Torcida N, Casalino G, Bondue A, et al.

    Frontiers in cardiovascular medicine 2023; (10()):1256862 doi:10.3389/fcvm.2023.1256862.

    PMID: 37829688
  72. 72

    Eosinophilic myocarditis: systematic review.

    Techasatian W, Gozun M, Vo K, et al.

    Heart (British Cardiac Society) 2024; (110(10)):687-693 doi:10.1136/heartjnl-2023-323225.

    PMID: 37963727
  73. 73

    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.

    Wechsler ME, Nair P, Terrier B, et al.

    The New England journal of medicine 2024; (390(10)):911-921 doi:10.1056/NEJMoa2311155.

    PMID: 38393328
  74. 74

    Hypereosinophilic syndrome associated with multiple thromboses requiring ICU admission: A case report.

    Ouanes I, Toumi S, Ben Cheikh Y, et al.

    La Tunisie medicale 2023; (101(10)):783-786.

    PMID: 38465762
  75. 75

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

    PMID: 38551368
  76. 76

    Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).

    Solans-Laqué R, Rúa-Figueroa I, Blanco Aparicio M, et al.

    European journal of internal medicine 2024; (128()):45-52 doi:10.1016/j.ejim.2024.06.008.

    PMID: 38880725
  77. 77

    [Eosinophilic granulomatosis with polyangiitis: a review article].

    Schindler V, Venhoff N

    Laryngo- rhino- otologie 2024; (103(10)):705-714 doi:10.1055/a-2214-1669.

    PMID: 38964344
  78. 78

    Literature review and case study of recurrent EPGA with elevated IgG4 and positive HBsAg successfully treated with rituximab.

    Wang J, Wang J, Wang N, et al.

    Renal failure 2024; (46(2)):2390569 doi:10.1080/0886022X.2024.2390569.

    PMID: 39169678
  79. 79

    Differential roles of eosinophils in cardiovascular disease.

    Xu J, Guo J, Liu T, et al.

    Nature reviews. Cardiology 2025; (22(3)):165-182 doi:10.1038/s41569-024-01071-5.

    PMID: 39285242
  80. 80

    Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.

    Kim DH, Kim S, Park S, et al.

    British journal of haematology 2024; (205(6)):2305-2314 doi:10.1111/bjh.19828.

    PMID: 39389908
  81. 81

    The Cleveland Clinic experience of eosinophilic myocarditis in the setting of hypereosinophilic syndrome: demographics, cardiac imaging, and outcomes.

    Reeder M, Okushi Y, Lo Presti Vega S, et al.

    Cardiovascular diagnosis and therapy 2024; (14(6)):1122-1133 doi:10.21037/cdt-24-347.

    PMID: 39790190
  82. 82

    Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.

    Wechsler ME, Silver J, Wolff G, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(8)):1052-1062 doi:10.1002/art.43146.

    PMID: 40008472
  83. 83

    Highlights from the plenary session: eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.

    Holle JU, Vaglio A

    Rheumatology (Oxford, England) 2025; (64(12 Suppl 2)):i92-i97 doi:10.1093/rheumatology/keae608.

    PMID: 40071429
  84. 84

    [Multidisciplinary expert consensus on diagnosis and treatment of eosinophilic granulomatosis with polyangiitis (2025 Edition)].

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2025; (48(5)):418-439 doi:10.3760/cma.j.cn112147-20250110-00027.

    PMID: 40300867
  85. 85

    Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.

    Shum M, Gewurz-Singer O, Silver J, Akuthota P

    Frontiers in medicine 2025; (12()):1568770 doi:10.3389/fmed.2025.1568770.

    PMID: 40630493
  86. 86

    Microangiopathic Anemia.

    Bommer M, Bloehdorn J

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2025; (52(4)):259-270 doi:10.1159/000544724.

    PMID: 40809448
  87. 87

    Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome.

    Stammler R, Vallée A, Rohmer J, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(11)):3066-3076.e2 doi:10.1016/j.jaip.2025.09.009.

    PMID: 40992688
  88. 88

    Organ-Restricted Hypereosinophilic Syndrome: A Case of Recurrent Hypereosinophilic Myopericarditis.

    Alhajri N, Fadlelseed S, Abokhater N, et al.

    JACC. Case reports 2025; (30(35)):105535 doi:10.1016/j.jaccas.2025.105535.

    PMID: 41003456
  89. 89

    Idiopathic hypereosinophilic syndrome complicated by computed tomography-negative cerebral infarction, strangulated intestinal obstruction, and hepatic portal venous gas: a case report of multi-system involvement.

    Wei H, Ji C, Dong F, et al.

    Quantitative imaging in medicine and surgery 2025; (15(11)):11630-11641 doi:10.21037/qims-2025-1070.

    PMID: 41209273
  90. 90

    Direct Fast Scarlet and Congo Red Staining in Identification of Eosinophils and Their Cell-Free Granules in Cardiac Tissue.

    Kumaki T, Abe T, Kashimura T, et al.

    International heart journal 2025; (66(6)):968-977 doi:10.1536/ihj.25-317.

    PMID: 41320336
  91. 91

    Updated treatment approaches for eosinophilic granulomatosis with polyangiitis: A systematic scoping review.

    Shiomi M, Higuchi T, Akiyama M, et al.

    Modern rheumatology 2026; (36(3)):415-421 doi:10.1093/mr/roaf126.

    PMID: 41427848
  92. 92

    Fulminant Idiopathic Hypereosinophilic Syndrome Presenting with Cardiac, Neurologic and Haematologic Involvement.

    Ibrahim N, Batri A, Rivera RR, Zwein A

    European journal of case reports in internal medicine 2025; (12(12)):006010 doi:10.12890/2025_006010.

    PMID: 41536447
  93. 93

    From hypereosinophilia to hypereosinophilic syndrome: real-world application of a two-tailed approach for HES diagnosis.

    Nicola S, Borrelli R, Ridolfi I, et al.

    Frontiers in immunology 2025; (16()):1735131 doi:10.3389/fimmu.2025.1735131.

    PMID: 41567200
  94. 94

    Persistent Hemorrhagic Lip Crusts as the Presenting Sign of Pediatric FIP1L1-PDGFRA-Positive Hypereosinophilic Syndrome: A Case Report and Review of the Literature.

    Chiang YK, Ho YH

    Pediatric dermatology 2026; (43(5)):1204-1208 doi:10.1111/pde.70233.

    PMID: 42014566
  95. 95

    MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.

    Gao M, Bachiashvili K, Jamy O, et al.

    Annals of hematology 2026; (105(5)).

    PMID: 42043473
  96. 96

    Hypereosinophilia of persistent/unknown cause: a bone marrow-based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing.

    Eletrebi MM, Sanchez-Ramirez J, Abdalla A, Holman CJ

    American journal of clinical pathology 2026; (165(5)) doi:10.1093/ajcp/aqag031.

    PMID: 42106910
  97. 97

    Organ Involvement and Constitutional Symptoms in Idiopathic Hypereosinophilic Syndrome: A 72-Patient Single-Centre Cohort.

    Łacwik P, Kupryś-Lipińska I, Kucharczyk A, et al.

    Journal of clinical medicine 2026; (15(14)) doi:10.3390/jcm15145569.

    PMID: 42513483
  98. 98

    Paraneoplastic Hypereosinophilia With Multisystem Involvement as an Atypical Presentation of Lung Adenocarcinoma.

    Bravo S, Machado A, Medeiros P, et al.

    Cureus 2026; (18(8)):e114369 doi:10.7759/cureus.114369.

    PMID: 42598653
  99. 99

    Idiopathic Hypereosinophilic Syndrome Presenting as Isolated Right Ventricular Endomyocardial Fibrosis With Intracavitary Thrombus: A Multimodality Imaging Case Report.

    Loudiyi N, Malki M, Erregui H, et al.

    Cureus 2026; (18(7)):e113350 doi:10.7759/cureus.113350.

    PMID: 42639520
  100. 100

    Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.

    Pongdee T, Silver J, Deb A, et al.

    Frontiers in allergy 2026; (7()):1843149 doi:10.3389/falgy.2026.1843149.

    PMID: 42657158
  101. 101

    Fulminant Eosinophilic Myocarditis in Steroid-Refractory Hypereosinophilic Syndrome: Navigating the Thrombotic Stage With Targeted Biologic Therapy.

    Althobaiti M, Aldlgan D, Alfehaid L, et al.

    JACC. Case reports 2026; (31(41)):109306 doi:10.1016/j.jaccas.2026.109306.

    PMID: 42667290
  102. 102

    Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis.

    Wigerinck S, Vandenberghe P

    European journal of haematology 2026; (117(6)):1485-1499 doi:10.1111/ejh.70299.

    PMID: 42677931
  103. 103

    Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.

    Wang H, Zhu F, Hu H

    Frontiers in cardiovascular medicine 2026; (13()):1924869 doi:10.3389/fcvm.2026.1924869.

    PMID: 42688267
  104. 104

    Déjà vu.

    Agrawal AO, Patankar AS, Samant R

    BMJ case reports 2026; (19(9)) doi:10.1136/bcr-2026-273616.

    PMID: 42749346
  105. 105

    Study outcomes for eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: towards achieving treatment goals in clinical practice.

    Cid MC, Hellmich B, Terrier B, et al.

    Autoimmunity reviews 2026; 104207 doi:10.1016/j.autrev.2026.104207.

    PMID: 42977011